ABSTRACT

Introduction

Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic CNV.

Areas covered

Review of preclinical studies and clinical trials data supporting the use of ranibizumab for myopic CNV. Discussion on the mechanisms, efficacy, safety, regulatory affairs, and future directions of ranibizumab for myopic CNV are highlighted.

Expert opinion

Ranibizumab has demonstrated good efficacy and safety profile in multiple clinical trials and long-term studies for treating myopic CNV. Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently available anti-VEGF agents, ranibizumab is the only drug that is approved for the treatment of myopic CNV by the US Food and Drug Administration. In the coming few years, biosimilars of ranibizumab may become available and will have the potential to lower the cost of ranibizumab. Long-term visual gain after ranibizumab treatment for myopic CNV is limited by chorioretinal atrophy associated with pathologic myopia and further research is required to tackle the development of chorioretinal atrophy.

中文翻译：

---

雷尼单抗治疗近视脉络膜新生血管

摘要

介绍

近视脉络膜新生血管（CNV）是病理性近视患者中最威胁视力的并发症之一。在过去的十年中，使用抗血管内皮生长因子（anti-VEGF）药物进行的抗血管生成治疗已成为近视CNV的标准治疗方法，而兰尼单抗已被批准用于治疗近视CNV。

覆盖区域

回顾临床前研究和临床试验数据，支持使用兰尼单抗治疗近视CNV。重点讨论了兰尼单抗治疗近视CNV的机理，功效，安全性，监管事务和未来方向。

专家意见

雷尼单抗已在治疗近视CNV的多项临床试验和长期研究中显示出良好的疗效和安全性。成本效益分析表明，兰尼单抗疗法是治疗近视CNV的经济有效方法。在目前可用的抗VEGF药物中，兰尼单抗是美国食品和药物管理局批准用于治疗近视CNV的唯一药物。在未来几年中，兰尼单抗的生物仿制药可能面世，并将有可能降低兰尼单抗的成本。雷尼单抗治疗近视CNV后的长期视力受到与病理性近视相关的脉络膜视网膜萎缩的限制，需要进一步研究以解决脉络膜视网膜萎缩的发展。